The Brand Name DAUNOCIN Has Generic Salt :: Daunorubicin 

DAUNOCIN  Is From Company Vhb Priced :: Rs. 375

DAUNOCIN have Daunorubicin is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

Indications for Drugs ::

Acute leukaemia, AIDS-related Kaposi’s sarcoma

Drug Dose ::

Adult: IV Acute leukaemia 30-45 mg/m2/day on days 1-3 of the induction regimen and days 1 and 2 of subsequent courses. May repeat course 3-6 wk later. Max total cumulative dose: 550 mg/m2 in patients w/o risk factors for cardiotoxicity and 400 mg/m2 in patients who have received chest radiotherapy. Child: For acute lymphoblastic leukaemia: 25 mg/m2 BSA once wkly in combination with other regimens. <2 yr old or BSA <0.5 m2: 1 mg/kg once wkly. Max (total cumulative dose): 300 mg/m2 and in children <2 yr: 10 mg/kg. Hepatic impairment: Based on serum bilirubin concentrations of 12-30 mcg/ml: 75% of the usual dose; >30 mcg/ml: 50% of the usual dose. AIDS-related Kaposi’s sarcoma As liposomal formulation: Initial: 40 mg/m2 every 2 wk. Continue treatment for as long as disease control is maintained. Hepatic impairment: Based on serum bilirubin concentrations of 12-30 mcg/ml: 75% of the usual dose; >30 mcg/ml: 50% of the usual dose.

Contraindication ::

Heart failure. Pregnancy, lactation.

Drug Precautions ::

Regular blood count and ECG monitoring; elderly, children. Hepatic or renal impairment may increase risk of toxicity. Pre-existing cardiac disease and previous treatment with doxorubicin. Myocardial toxicity leading to potentially fatal congestive heart failure may occur during therapy or mth to yr after therapy cessation. Incidence of myocardial toxicity increases after total cumulative dose exceeds 400-550 mg/m2 in adults, 300 mg/m2 in children >2 yr, or 10 mg/kg in children <2 yr. Risk of severe myelosuppression leading to infection or haemorrhage. Drug Side Effects ::

GI disturbances; stomatitis; alopoecia and dermatological reactions. Extravasation of daunorubicin may cause severe local tissue necrosis damaging surrounding muscles, tendons and nerves. IV infusion, back pain, flushing and chest tightness. Potentially Fatal: Bone marrow suppression, cardiac toxicity, cardiomyopathy and congestive heart failure.

Pregnancy category ::

4

Drug Mode of Action ::  

Daunorubicin forms a stable complex with DNA and interferes with the nucleic acid synthesis. It is a cell-cycle nonspecific agent, but its cytotoxic effects are mostly marked in the S-phase. It also has immunosuppressant and antibacterial effects.

Drug Interactions ::

Increased risk of cardiotoxicity when used with cyclophosphamide. Increased risk of hepatic toxicity when used with hepatotoxic drugs e.g. high-dose methotrexate. Potentially Fatal: Immunisation with live vaccines is not recommended. Concurrent radiation may lead to increased radiation reaction.